GSK3B Knockout HAP1 Cell Line

The choice depends on whether you are studying GSK3B (glycogen synthase kinase 3β)'s role as a constitutively active serine/threonine kinase or its functions in Wnt signaling, insulin signaling, neurodegeneration, and lithium pharmacology. The Knockout line is the standard tool for asking whether GSK3β is required for these processes — GSK3β is a constitutively active kinase (atypically) that phosphorylates >100 substrates including β-catenin (Wnt pathway destruction complex), tau (AD pathology), glycogen synthase (insulin/glycogen metabolism), and many others; GSK3β is inhibited by PI3K-AKT-mediated S9 phosphorylation. Overexpression is useful for studying GSK3β gain-of-function effects. Important consideration: GSK3α (GSK3A) paralog expression analysis is essential given substantial functional overlap. Rescue with wild-type, kinase-dead, or S9A (constitutively active, non-inhibitable) GSK3β enables comprehensive structure-function studies. The knockout is a critical specificity control for lithium (the gold-standard mood stabilizer that directly inhibits GSK3β), tideglusib (clinical GSK3 inhibitor for AD and progressive supranuclear palsy), and emerging GSK3-targeted therapeutics in psychiatric and neurodegenerative disease.

Primary applications: • Wnt/β-catenin signaling: β-catenin stabilization and TCF/LEF reporter analysis given GSK3β's role in the β-catenin destruction complex. • Phospho-substrate analysis: phospho-β-catenin (S33/S37/T41) and phospho-tau (S396) Western blot to characterize GSK3β kinase activity. • Lithium specificity: critical genetic control for lithium (gold-standard mood stabilizer; direct GSK3β inhibitor at therapeutic concentrations). • GSK3 inhibitor specificity: critical genetic control for tideglusib, AR-A014418, CHIR99021, and other GSK3 inhibitors in clinical and preclinical development. EDITGENE recommends this model for researchers investigating GSK3β biology, Wnt pathway regulation, and GSK3-targeted psychiatric/neurodegenerative drug development.

Yes. GSK3β rescue experiments are well-established for kinase research: • Construct design: use a codon-modified GSK3B sequence with a small C-terminal tag (FLAG, HA). GSK3β has N-terminal regulatory S9 phospho-site, central kinase domain, and C-terminal region — preserve all elements. • Kinase-dead rescue: K85R or D200A mutations abolish catalytic activity and serve as the standard specificity control. • Constitutively active rescue: S9A mutation removes the autoinhibitory PI3K-AKT-mediated phosphorylation site, generating constitutively active GSK3β — invaluable for separating PI3K-AKT-regulated from constitutively active GSK3β functions. • Functional readout: rescue should restore β-catenin phosphorylation, tau phosphorylation, and lithium sensitivity. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.